If you have been reading about drug affinity complex and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-12-15. Numbers and descriptions here follow the published literature rather than marketing material.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | GHRH receptor agonist |
| Sequence length | 29 amino acids | Derived from human GHRH |
| Molecular weight | About 3368 Da without linker | Albumin-binding form is heavier |
| Appearance | White to off-white lyophilized powder | Common form for research reference material |
| Typical storage | -20 °C or below, desiccated | Protect powder from light and moisture |
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
== Habitat and distribution == Xanthoria parietina is a cosmopolitan species reported from Australia, Africa, Asia, North America, and throughout much of Europe. In eastern North America and Europe, it is more frequently encountered near coastal locations, and in Southern Ontario, Canada, its reappearance has been attributed to increased nitrate deposition associated with industrial and agricultural developments. The species shows a strong preference for coastal habitats, where it benefits from marine aerosol deposition. In Maine, USA, X. parietina is abundant on gravestones near the ocean but declines sharply further inland. It becomes rare beyond 40 km (25 mi) from the coast in southwestern Maine and 130 km (81 mi) inland in eastern Maine. This inland distribution pattern is largely influenced by the deposition of marine-derived nutrients, particularly chloride and sodium, which are transported inland by wind and precipitation. In North America, the species was historically limited primarily to coastal regions—along the Atlantic coast from Newfoundland to Pennsylvania, along the Pacific coast from California to the Pacific Northwest, and in a small part of the Gulf coast in Texas. Within the Pacific Northwest, its traditional range was described as west of the Cascades, from the Willamette Valley to the Puget Sound region. Since the early 2000s, however, the species has been documented in several inland cities in Idaho, Washington, and parts of western Montana.
Sibabrata Mukhopadhyay, Mumu Chakraborty, Arun Bandyopadhyay, Dipak Kar, Tanima Banerjee, Aditya Konar, Debaprasad Jana, Siddhartha Roy, Santu Bandyopadhyay, Balram Ghosh, Mabalirajan Ulaganathan, Rakesh Johri, Subhash Sharma, Gurdarshan Singh, Bholanath Paul, Vasanta Madhava Sharma Gangavaram, Jhillu Singh Yadav, Radha Krishna Palakodety (August 2013). "Method for treatment of bronchial asthma (Patent US8519154B2)". {{cite journal}}: Cite journal requires |journal= (help)CS1 maint: multiple names: authors list (link) Sujoy K Das Gupta, Abhik Saha, Archana Sharma, Siddhartha Roy, Bhabatarak Bhattacharya (January 2012). "Peptide antagonists for inhibiting heat shock protein (Hsp 16.3) of Mycobacterium tuberculosis (Patent 7569537)". Retrieved 15 October 2016.{{cite web}}: CS1 maint: multiple names: authors list (link) S. Bandyopadhay, B. Ghosh, Parasuraman Jaisankar, Bikas C Pal, Siddhartha Roy, Nath Paul, Arjun Ram, U. Mabalirajan, Nahid Ali, Arun Bandyopadhyay, Aditya Konar, J. B. Chakraborty, I. C. Mukherjee, Jaydeep Chaudhuri, Sanjit Kumar Mahato, A. Manna, Roma Sinha, Pradyot Bhattacharya, J. Vinayagam, Sudeshna Chowdhury (January 2012). "Substituted catechols as inhibitors of IL-4 and IL-5 for the treatment of bronchial asthma (WO Patent 2,012,140,574)". doi:10.13140/RG.2.1.2784.6488. Retrieved 15 October 2016. {{cite journal}}: Cite journal requires |journal= (help)CS1 maint: multiple names: authors list (link) 1st S. Bandyopadhay, B. Ghosh, Parasuraman Jaisankar, Bikas C Pal, Siddhartha Roy, Nath Paul, Arjun Ram, U.
=== Human growth hormone (hGH) === Human growth hormone is a naturally occurring hormone that is responsible for general body growth in both men and women. hGH helps the body protein while breaking down fat deposits. Too much hGH results in increased muscle mass.
Sources: en.wikipedia.org
Moscow, as the city designated by the Constitution of the Russian Federation as the seat of federal authority, contains the country's federal legislative, executive, and judicial authorities—except for the Constitutional Court of the Russian Federation, which has been located in Saint Petersburg since 2008. The supreme executive authority—the Government of the Russian Federation—is located in the House of the Government of the Russian Federation (the White House) on the Krasnopresnenskaya Embankment in the center of Moscow. The State Duma is on Okhotny Ryad (street). The Federation Council is in a building on Bolshaya Dmitrovka (street). The Supreme Court of the Russian Federation is also in Moscow. The Moscow Kremlin is the official residence of the President of the Russian Federation. The president's working residence in the Kremlin is located in the Senate Palace.
No natural reservoir for SARS-CoV-2 has been identified. Prior to the emergence of SARS-CoV-2 as a pathogen infecting humans, there had been two previous zoonosis-based coronavirus epidemics, those caused by SARS-CoV-1 and MERS-CoV. The first known infections from SARS‑CoV‑2 were discovered in Wuhan, China. The nature of the virus's origins remain unclear and disputed. The original source of viral transmission to humans remains unclear, as does whether the virus became pathogenic before or after the spillover event. Because many of the early infectees were workers at the Huanan Seafood Market, it has been suggested that the virus might have originated from the market. Other research indicates that visitors may have introduced the virus to the market, which then facilitated rapid expansion of the infections. A March 2021 WHO-convened report stated that human spillover via an intermediate animal host was the most likely explanation, with direct spillover from bats next most likely. Introduction through the food supply chain and the Huanan Seafood Market was considered another possible, but less likely, explanation. Later analysis in November 2021 said that the earliest-known case had been misidentified and that the preponderance of early cases linked to the Huanan Market argued for it being the source. For a virus recently acquired through a cross-species transmission, rapid evolution is expected. The mutation rate estimated from early cases of SARS-CoV-2 was of 6.54×10−4 per site per year.
Urotensin II-related peptide (URP) is a hormone that in humans is encoded by the gene UTS2B. URP is a cyclic neuropeptide that is found in all vertebrates that have been genome sequenced so far. It has a long lasting hypotensive effect and may also regulate reproduction. It is part of the Urotensin II system and is one of the two endogenous ligands for rats, mice, and possibly humans.
=== Liquid interfaces === Understanding the behavior of nanoparticles at liquid interfaces is essential for integrating them into electronics, optics, sensing, and catalysis devices. Molecular arrangements at liquid/liquid interfaces are uniform. Often, they also provide a defect-correcting platform and thus, liquid/liquid interfaces are ideal for self-assembly. Upon self-assembly, the structural and spatial arrangements can be determined via X-ray diffraction and optical reflectance. The number of nanoparticles involved in self-assembly can be controlled by manipulating the concentration of the electrolyte, which can be in the aqueous or the organic phase. Higher electrolyte concentrations correspond to decreased spacing between the nanoparticles. Pickering and Ramsden worked with oil/water (O/W) interfaces to portray this idea. Pickering and Ramsden explained the idea of pickering emulsions when experimenting with paraffin-water emulsions with solid particles like iron oxide and silicon dioxide. They observed that the micron-sized colloids generated a resistant film at the interface between the two immiscible phases, inhibiting the coalescence of the emulsion drops. These Pickering emulsions are formed from the self-assembly of colloidal particles in two-part liquid systems, such as oil-water systems. The desorption energy, which is directly related to the stability of emulsions depends on the particle size, particles interacting with each other, and particles interacting with oil and water molecules.
Sources: en.wikipedia.org
=== Internal rectal prolapse and external rectal prolapse are separate conditions === The main evidence for the theory that IRP and external rectal prolapse are separate entities is that it is rare for IRP to later progress to ERP. In one study, out of 30 cases of IRP which were managed without surgery, two of them (6.7%) went on to develop ERP after an average of 5.8 years. Another study reported that only 1 out of 26 such cases later developed external rectal prolapse after a mean follow up time of 3.8 years, giving a rate of 3.8%. However, these reported rates of progression from IRP to external rectal prolapse have been criticized. In these studies, the more severe cases of IRP were treated surgically, while less significant cases of IRP were treated without surgery and placed under long term review. Therefore, the true rate of progression of clinically significant IRP into external rectal prolapse without any surgical intervention is unknown. Furthermore, the timeline of progression from IRP to external rectal prolapse may take decades; such a period of time exceeds the duration of most studies. It is possible that this rate might be higher if follow-up was longer. Also, no case has been documented which proves progression through all of these stages over time in the same individual. Up to 50% of healthy people demonstrate some degree of IRP during defecography. However, this figure drops to 18% when more modern criteria for clinically significant IRP are used.
The variation in the 14C/12C ratio in different parts of the carbon exchange reservoir means that a straightforward calculation of the age of a sample based on the amount of 14C it contains will often give an incorrect result. There are several other possible sources of error that need to be considered. The errors are of four general types:
In an interview with Al Jazeera on 19 September, Mohsen Rezaei stated that they had conveyed three conditions to Washington via Qatar—including an end to the war on all fronts, the unfreezing of their assets, and the lifting of the naval blockade—and were awaiting a response from President Trump.
Sources: en.wikipedia.org
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.
The label was first attached to the albumin-binding form during early development work. A shorter analog without the linker later became known by the same name in informal use. Published papers normally state which version was studied, so the methods section resolves the ambiguity.
It is a synthetic peptide rather than a steroid, and it does not occur naturally in the body. Its sequence is derived from a hypothalamic hormone called growth hormone-releasing hormone. It works as a receptor agonist rather than as a replacement for that hormone.
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.